The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma. The U.S.
The FDA has granted fast track designation (FTD) to LBL-034, an investigational GPRC5D/CD3 bispecific T-cell engager (BiTE), for patients with relapsed/refractory multiple myeloma (R/R MM).
GMP ActiveMax ® Human T Cell Activation/Expansion CD3/CD28 Beads are uniform 5.5 μm magnetic beads coated with an optimized mixture of GMP-grade mouse monoclonal antibodies targeting CD3 and CD28, ...
Biomunex's CSO, Dr. Simon Plyte, is invited to present an oral communication during the 11th Annual Oncology Innovation Forum on the 10th of January 2026 in San Francisco (USA). -- The oral ...
NANJING, China, April 15, 2025 /PRNewswire/ -- ProBio, a global leader in the antibody discovery and development, is pleased to announce its upcoming poster presentation at the American Association ...
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active ...
Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...
Metabolism guides the activation states of regulatory T cells, the immune cells that prevent inappropriate activation of the immune system. St. Jude Children's Research Hospital scientists recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results